EMAIL THIS PAGE TO A FRIEND

Journal of chromatography. A

Multi-residue analytical methodology-based liquid chromatography-time-of-flight-mass spectrometry for the analysis of pharmaceutical residues in surface water and effluents from sewage treatment plants and hospitals.


PMID 24768127

Abstract

An analytical method that facilitated the analysis of 11 pharmaceuticals residue (caffeine, prazosin, enalapril, carbamazepine, nifedipine, levonorgestrel, simvastatin, hydrochlorothiazide, gliclazide, diclofenac-Na, and mefenamic acid) with a single pre-treatment protocol was developed. The proposed method included an isolation and concentration procedure using solid phase extraction (Oasis HLB), a separation step using high-performance liquid chromatography, and a detection procedure that applies time-of-flight mass spectrometry. The method was validated for drinking water (DW), surface water (SW), sewage treatment plant (STP) influent and effluent, and hospital (HSP) influent and effluent. The limits of quantification were as low as 0.4, 1.6, 5, 3, 2.2 and 11 ng/L in DW, SW, HSP influent and effluent, STP effluent, and STP influent, respectively. On average, good recoveries higher than 75% were obtained for most of the target analytes in all matrices. Matrix effect was evaluated for all samples matrices. The proposed method successfully determined and quantified the target compounds in raw and treated wastewater of four STPs and three hospitals in Malaysia, as well as in two SW sites. The results showed that a number of the studied compounds pose moderate to high persistency in sewage treatment effluents as well as in the recipient rivers, namely; caffeine, simvastatin, and hydrochlorothiazide. Ten out of 11 compounds were detected and quantified in 13 sampling points. Caffeine was detected with the highest level, with concentrations reaching up to 9099 ng/L in STP influent.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

93784
Caffeine, PharmaGrade, EP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production
C8H10N4O2
C0750
Caffeine, powder, ReagentPlus®
C8H10N4O2
C8960
Caffeine, BioXtra
C8H10N4O2
C0100000
Caffeine, European Pharmacopoeia (EP) Reference Standard
C8H10N4O2
C7731
Caffeine, meets USP testing specifications, anhydrous
C8H10N4O2
1085003
Caffeine, United States Pharmacopeia (USP) Reference Standard
C8H10N4O2
PHR1009
Caffeine, Pharmaceutical Secondary Standard; Certified Reference Material
C8H10N4O2
56396
Caffeine, certified reference material, TraceCERT®
C8H10N4O2
05-0370
Caffeine, SAJ special grade, ≥98.5%
C8H10N4O2
Y0000787
Caffeine for system suitability, European Pharmacopoeia (EP) Reference Standard
C8H10N4O2
1086006
Caffeine melting point standard, United States Pharmacopeia (USP) Reference Standard
C8H10N4O2
PHR1095
Caffeine Melting Point Standard, Pharmaceutical Secondary Standard; Certified Reference Material
C8H10N4O2
C4024
Carbamazepine, powder
C15H12N2O
94496
Carbamazepine, analytical standard
C15H12N2O
C8981
Carbamazepine, meets USP testing specifications
C15H12N2O
C0450000
Carbamazepine, European Pharmacopoeia (EP) Reference Standard
C15H12N2O
1093001
Carbamazepine, United States Pharmacopeia (USP) Reference Standard
C15H12N2O
PHR1067
Carbamazepine, Pharmaceutical Secondary Standard; Certified Reference Material
C15H12N2O
N2260
D(−)-Norgestrel, analytical standard
C21H28O2
1235300
Enalapril maleate, United States Pharmacopeia (USP) Reference Standard
C20H28N2O5 · C4H4O4
E0109000
Enalapril maleate, European Pharmacopoeia (EP) Reference Standard
C20H28N2O5 · C4H4O4
PHR1289
Enalapril Maleate, Pharmaceutical Secondary Standard; Certified Reference Material
C20H28N2O5 · C4H4O4
G2167
Gliclazide, powder, ≥98%
C15H21N3O3S
G0326000
Gliclazide, European Pharmacopoeia (EP) Reference Standard
C15H21N3O3S
H4759
Hydrochlorothiazide, crystalline
C7H8ClN3O4S2
H2910
Hydrochlorothiazide, meets USP testing specifications
C7H8ClN3O4S2
H1200000
Hydrochlorothiazide, European Pharmacopoeia (EP) Reference Standard
C7H8ClN3O4S2
1314009
Hydrochlorothiazide, United States Pharmacopeia (USP) Reference Standard
C7H8ClN3O4S2
PHR1032
Hydrochlorothiazide, Pharmaceutical Secondary Standard; Certified Reference Material
C7H8ClN3O4S2
Y0001494
Hydrochlorothiazide for peak identification, European Pharmacopoeia (EP) Reference Standard
C7H8ClN3O4S2